Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD.

Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin-Asp PG, Chen YH, Duong DM, Seyfried NT, Powers MA, Kukar T, Hales CM, Gearing M, Cairns NJ, Boylan KB, Dickson DW, Rademakers R, Zhang YJ, Petrucelli L, Sattler R, Zarnescu DC, Glass JD, Rossoll W.

Nat Neurosci. 2018 Feb;21(2):228-239. doi: 10.1038/s41593-017-0047-3. Epub 2018 Jan 8.

PMID:
29311743
2.

A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain.

Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, Seyfried NT.

EMBO Mol Med. 2018 Jan;10(1):48-62. doi: 10.15252/emmm.201708202.

3.

Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.

Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD.

Neurology. 2016 Sep 6;87(10):1024-30. doi: 10.1212/WNL.0000000000003067. Epub 2016 Aug 3.

Supplemental Content

Support Center